Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Development and Diagnostic Evaluation of a Novel Quantifiable Ultrasound Based Multi-parametric Biomarker for Hepatic Steatosis in Patients With Suspected MASLD ( LYNX )

NCT07270601 is registered in ClinicalTrials.gov with ContextVision AB as lead sponsor.

NCT NCT07270601
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07270601 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Development and Diagnostic Evaluation of a Novel Quantifiable Ultrasound Based Multi-parametric Biomarker for Hepatic Steatosis in Patients With Suspected MASLD ( LYNX )
Lead sponsor
ContextVision AB
Phase
Not applicable
Overall status
Recruiting
Start date
November 17, 2025
Completion date
December 31, 2026
Enrollment
110 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

masld - metabolic dysfunction-associated steatotic liver disease, nafld - non-alcoholic fatty liver disease